JP2024521092A5 - - Google Patents

Info

Publication number
JP2024521092A5
JP2024521092A5 JP2023571661A JP2023571661A JP2024521092A5 JP 2024521092 A5 JP2024521092 A5 JP 2024521092A5 JP 2023571661 A JP2023571661 A JP 2023571661A JP 2023571661 A JP2023571661 A JP 2023571661A JP 2024521092 A5 JP2024521092 A5 JP 2024521092A5
Authority
JP
Japan
Prior art keywords
target
salt
compound
moi
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571661A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521092A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030070 external-priority patent/WO2022246086A1/en
Publication of JP2024521092A publication Critical patent/JP2024521092A/ja
Publication of JP2024521092A5 publication Critical patent/JP2024521092A5/ja
Pending legal-status Critical Current

Links

JP2023571661A 2021-05-19 2022-05-19 細胞傷害性薬剤を送達するためのｍａｔｅｓ技術を使用する抗体薬物コンジュゲート Pending JP2024521092A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163190703P 2021-05-19 2021-05-19
US63/190,703 2021-05-19
PCT/US2022/030070 WO2022246086A1 (en) 2021-05-19 2022-05-19 Antibody drug conjugates using mates technology for delivering cytotoxic agents

Publications (2)

Publication Number Publication Date
JP2024521092A JP2024521092A (ja) 2024-05-28
JP2024521092A5 true JP2024521092A5 (enExample) 2025-05-26

Family

ID=84141792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571661A Pending JP2024521092A (ja) 2021-05-19 2022-05-19 細胞傷害性薬剤を送達するためのｍａｔｅｓ技術を使用する抗体薬物コンジュゲート

Country Status (12)

Country Link
US (1) US20250108124A1 (enExample)
EP (1) EP4340859A4 (enExample)
JP (1) JP2024521092A (enExample)
KR (1) KR20240012381A (enExample)
CN (1) CN117412761A (enExample)
AU (1) AU2022277698A1 (enExample)
BR (1) BR112023023525A2 (enExample)
CA (1) CA3219550A1 (enExample)
IL (1) IL307884A (enExample)
MX (1) MX2023013270A (enExample)
PH (1) PH12023553153A1 (enExample)
WO (1) WO2022246086A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12023553152A1 (en) * 2021-05-17 2024-03-11 Biohaven Therapeutics Ltd Compositions including conjugated therapy enhancers
AU2024263915A1 (en) * 2023-04-23 2025-11-20 Biohaven Therapeutics Ltd. Antibody-drug conjugates for delivering cytotoxic agents
WO2026150353A2 (en) 2025-01-11 2026-07-16 Biohaven Therapeutics Ltd. Antibody-drug conjugates for delivering cytotoxic agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2605443T3 (es) * 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
WO2007147901A1 (en) * 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP2497775A1 (en) * 2011-03-11 2012-09-12 Ruprecht-Karls-Universität Heidelberg Ferrocene-based compounds and their use as ROS regulating prodrugs
CN102936281B (zh) * 2012-10-25 2013-12-25 浙江大学 一种rTRAIL突变体及其海兔毒素偶联物
EP3193940A1 (en) * 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CA2966005C (en) * 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
EP3991748A3 (en) * 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
CA3061467A1 (en) * 2017-04-28 2019-10-24 Ajinomoto Co., Inc. Compound having affinity substance to soluble protein, cleavable portionand reactive group, or salt thereof
WO2019241609A1 (en) * 2018-06-15 2019-12-19 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
EP3894427A1 (en) * 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
CA3143513A1 (en) * 2019-07-03 2021-01-07 Kleo Pharmaceuticals, Inc. Cd38-binding agents and uses thereof
KR20220103986A (ko) * 2019-11-18 2022-07-25 클레오 파마슈티컬스 인코포레이티드 지정 접합 기술

Similar Documents

Publication Publication Date Title
JP7708133B2 (ja) 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP6647208B2 (ja) 抗ｉｌ−１７抗体、その生産および使用のための方法
CN102946858B (zh) 含有免疫球蛋白Fc的多肽的液体制剂
JP6328648B2 (ja) 新規薬物−タンパク質コンジュゲート
JP2004248677A5 (enExample)
CA3103151A1 (en) Compound having affinity substance to antibody and bioorthogonal functional group, or salt thereof
JP2022518743A (ja) 抗体－薬物コンジュゲート用のグリコシド含有ペプチドリンカー
DE60141043D1 (de) Rekombinante anti-cd30-antikörper und deren verwendungen
RU2010122053A (ru) Иммуносупрессорные полипептиды и нуклеиновые кислоты
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
JP2016513635A (ja) 低濃度抗体製剤
JP7605290B2 (ja) 化合物またはその塩、およびそれらにより得られる抗体
WO2021080008A1 (ja) １価ｃｃａｐ生成物の製造方法
JP2020509010A5 (enExample)
JP2025512735A5 (enExample)
JP7356677B2 (ja) 複合体
AU2026202991A1 (en) Compound or salt thereof, and antibody produced using same
JP2021535108A5 (enExample)
JP2024519814A5 (enExample)
JP2024519031A5 (enExample)
CA3219517A1 (en) Agents for directed conjugation techniques and conjugated products
DE69816241T2 (de) Aktivierte peptide und konjugate
AU2022207278A1 (en) Compound or salt thereof, and antibody obtained therefrom
JP2023501720A5 (enExample)
CN118742329A (zh) 包含抗组织因子抗体-药物缀合物的药物组合物